MANY MINDEDEarly drug trial shows visceral fat reduction
In two small randomized trials, participants receiving CBL-514 injections every three weeks lost 63 milliliters of visceral fat total from baseline by eight to twelve weeks. The placebo group gained 78 milliliters during the same period. CBL-514 induced apoptosis in visceral adipocytes—fat cells that cluster around organs and carry higher health risks—while participants ranged from healthy weight to overweight. MRI measurements showed the drug group lost 71 milliliters of visceral fat by four weeks (12% decrease), whereas the placebo group gained 31 mill liters (6% increase). Results were presented at the European Association for the Study of Diabetes meeting in Milan on October 1, 2026, though the date appears future-dated relative to current context.
The mechanism targets visceral fat specifically, which is distinct from subcutaneous fat. While prior trials observed subcutaneous fat reduction, this drug’s effect on visceral fat—linked to diabetes and heart disease—shows potential for improved metabolic health. Larger trials for safety and efficacy are ongoing, meaning current results do not yet validate the drug’s impact across broader populations.
This progress matters for health access because visceral fat reduction could make diabetes and heart disease prevention more achievable for people with excess visceral fat. If confirmed in larger studies, it might offer a new tool for managing conditions that affect millions globally. However, the small sample size and future-dated reporting mean the full benefit for public health remains unproven. Next steps include larger trials to confirm whether visceral fat reduction translates to reduced disease risk in diverse populations.
Source: Science News